Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.

Rosemina MerchantCarole GalliganManjunatha Ankathatti MunegowdaL Bruce PearcePeter LloydPaul SmithFahar MerchantMinh D To

Published in: Journal for immunotherapy of cancer (2022)

MDNA11 is a next generation long-acting IL-2 immunotherapeutic with a highly favorable pharmacodynamic profile that translates to a strong therapeutic efficacy in preclinical tumor models and a strong and durable immune response in NHP.

Keyphrases

immune response
endothelial cells
dendritic cells
toll like receptor
air pollution
induced pluripotent stem cells
high fat diet induced
pluripotent stem cells
cell therapy
stem cells
skeletal muscle
mesenchymal stem cells
bone marrow
adipose tissue
wild type
insulin resistance